Recent Annual Reports

Browse the latest SEC filings with AI-powered analysis. Get insights into corporate performance, financial trends, and business developments.

📊 4721 Reports
🤖 AI Analyzed
Recent
📄 Page 76 of 394

Key Highlights

  • Diversified portfolio with no single borrower exceeding 10% of the loan pool
  • Reserve Account fully funded to mitigate potential collection shortfalls
  • Clear path to maturity with an option to close the trust once loans drop below 1...
Read Analysis
🤖 AI Generated

Key Highlights

  • Backed by federal government guarantees of at least 97% on most loans.
  • Stable, predictable cash flow generated from a diversified pool of student loans...
  • Senior/Subordinate structure provides enhanced protection for Class A bondholder...
Read Analysis
🤖 AI Generated

Key Highlights

  • Steady cash flow generated from a $1.2 billion student loan pool.
  • Loan defaults remain stable within the expected 2% to 4% annual range.
  • Self-contained financial structure with no corporate debt and built-in reserve f...
Read Analysis
🤖 AI Generated

Key Highlights

  • Investment in a diversified pool of federal student loans with no single borrowe...
  • Backed by a $3.2 million reserve account to ensure stability in interest payment...
  • The trust is nearing the end of its lifecycle, focusing on consistent cash flow ...
Read Analysis
🤖 AI Generated
PAVmed Inc.
10-K March 27, 2026

Key Highlights

  • Significant revenue growth from $0.7 million to $2.8 million year-over-year
  • Majority ownership of Lucid Diagnostics, a high-potential medical tech subsidiar...
  • Active expansion of EsoGuard Testing Centers to drive commercial adoption
Read Analysis
🤖 AI Generated

Key Highlights

  • Consistent performance with all interest and principal payments met.
  • Low borrower default rates aligned with original 2015 projections.
  • Investment-grade ratings maintained for Class A notes.
Read Analysis
🤖 AI Generated

Key Highlights

  • High credit quality with 97% of loans backed by U.S. government guarantees.
  • Consistent performance in 'run-off' mode with all investor obligations met.
  • Fully funded reserve account ensures stability against temporary cash shortages.
Read Analysis
🤖 AI Generated
Entera Bio Ltd.
10-K March 27, 2026

Key Highlights

  • Proprietary N-Tab® technology enables oral delivery of proteins and peptides, re...
  • Lead drug candidate EB613 successfully increased bone density in early trials an...
  • Potential for platform expansion into high-growth markets like weight-loss treat...
Read Analysis
🤖 AI Generated
GD Culture Group Ltd
10-K March 27, 2026

Key Highlights

  • Strategic pivot from legacy livestreaming to AI-driven interactive reading and B...
  • Acquisition of Pallas Capital added 7,500 Bitcoin to the corporate balance sheet...
  • Tripled R&D investment to $2.3 million to accelerate AI-powered storytelling pla...
Read Analysis
🤖 AI Generated

Key Highlights

  • Backed by federal student loans with a 97% government guarantee on principal and...
  • Passive financial structure designed for predictable, steady cash flow to invest...
  • Operational systems are confirmed to be functioning correctly and meeting indust...
Read Analysis
🤖 AI Generated

Key Highlights

  • Successfully restructured over $150 million in debt in 2022 to extend payment de...
  • Operates a vertically integrated cannabis model across 32 dispensaries in key U....
  • Strategic focus on streamlining operations and exiting non-profitable markets to...
Read Analysis
🤖 AI Generated
Biodexa Pharmaceuticals Plc
20-F March 27, 2026

Key Highlights

  • Clinical-stage drug developer focused on MidaSolve and MidaCore platforms.
  • Lead drug candidates MTX228 and MTX230 represent the core value of the company's...
  • Active global operations spanning the UK, Australia, Ireland, and the US.
Read Analysis
🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from annual reports with our AI-powered analysis. Track corporate performance, financial trends, and strategic developments.

Back to Homepage